[go: up one dir, main page]

WO2006010147A3 - Gestion de la formation d'un biofilm - Google Patents

Gestion de la formation d'un biofilm Download PDF

Info

Publication number
WO2006010147A3
WO2006010147A3 PCT/US2005/024946 US2005024946W WO2006010147A3 WO 2006010147 A3 WO2006010147 A3 WO 2006010147A3 US 2005024946 W US2005024946 W US 2005024946W WO 2006010147 A3 WO2006010147 A3 WO 2006010147A3
Authority
WO
WIPO (PCT)
Prior art keywords
bacterium
preventing
modulating
expression
biofilm formation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/024946
Other languages
English (en)
Other versions
WO2006010147A2 (fr
Inventor
Gary R Eldridge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/085,279 external-priority patent/US7604978B2/en
Priority claimed from US11/133,858 external-priority patent/US20060264411A1/en
Application filed by Individual filed Critical Individual
Priority to EP05791709A priority Critical patent/EP1773313A4/fr
Priority to CA002573494A priority patent/CA2573494A1/fr
Publication of WO2006010147A2 publication Critical patent/WO2006010147A2/fr
Publication of WO2006010147A3 publication Critical patent/WO2006010147A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)

Abstract

L'invention porte: sur un procédé réduisant ou prévenant l'invasion de bactéries dans un tissu, consistant à moduler l'expression du gène cysB dans la bactérie; sur un procédé in vivo de réduction ou prévention chez un patient le nécessitant d'une infection bactérienne chronique, consistant à moduler l'expression du gène cysB dans une cellule capable de former un biofilm; et sur un procédé de gestion ou prévention chez un patient le nécessitant d'une infection bactérienne chronique, consistant à moduler l'expression d'un gène cysB dans une bactérie cause de l'infection bactérienne.
PCT/US2005/024946 2004-07-14 2005-07-14 Gestion de la formation d'un biofilm Ceased WO2006010147A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP05791709A EP1773313A4 (fr) 2004-07-14 2005-07-14 Gestion de la formation d'un biofilm
CA002573494A CA2573494A1 (fr) 2004-07-14 2005-07-14 Gestion de la formation d'un biofilm

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US58768004P 2004-07-14 2004-07-14
US60/587,680 2004-07-14
US60976304P 2004-09-14 2004-09-14
US60/609,763 2004-09-14
US11/085,279 2005-03-21
US11/085,279 US7604978B2 (en) 2004-07-14 2005-03-21 Inhibition of biofilm formation
US11/133,858 2005-05-20
US11/133,858 US20060264411A1 (en) 2005-05-20 2005-05-20 Control of biofilm formation

Publications (2)

Publication Number Publication Date
WO2006010147A2 WO2006010147A2 (fr) 2006-01-26
WO2006010147A3 true WO2006010147A3 (fr) 2006-07-06

Family

ID=35785807

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2005/024946 Ceased WO2006010147A2 (fr) 2004-07-14 2005-07-14 Gestion de la formation d'un biofilm
PCT/US2005/024945 Ceased WO2006019881A2 (fr) 2004-07-14 2005-07-14 Compositions et methodes de traitement des biofilms et des infections bacteriennes

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2005/024945 Ceased WO2006019881A2 (fr) 2004-07-14 2005-07-14 Compositions et methodes de traitement des biofilms et des infections bacteriennes

Country Status (3)

Country Link
EP (1) EP1773313A4 (fr)
CA (1) CA2573494A1 (fr)
WO (2) WO2006010147A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110141572A (zh) * 2019-06-20 2019-08-20 牡丹江医学院 一种治疗哮喘的药物及其制备方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7604978B2 (en) 2004-07-14 2009-10-20 Sequoia Sciences, Inc. Inhibition of biofilm formation
CA2580078A1 (fr) 2004-09-14 2006-03-23 Gary R. Eldridge Composes, compositions et procedes destine a reguler des films biologiques et a prevenir des infections bacteriennes
TWI413646B (zh) * 2010-09-03 2013-11-01 Univ China Medical 用於抑制基質金屬蛋白酶活性及／或生成、抑制有絲分裂原活化蛋白激酶磷酸化、及／或促進膠原蛋白生成之醫藥組合物及其用途
CN102784096B (zh) * 2011-05-18 2016-10-12 上海现代药物制剂工程研究中心有限公司 一种积雪草酸自微乳化给药系统及其制备方法
US8324264B1 (en) 2011-07-22 2012-12-04 Sequoia Sciences, Inc. Inhibitors of bacterial biofilms and related methods
WO2013021258A1 (fr) * 2011-08-05 2013-02-14 Council Of Scientific & Industrial Research Composés antituberculeux
EP2712863B1 (fr) * 2012-09-28 2014-10-22 Sequoia Sciences, Inc. Nouveaux inhibiteurs de biofilms bactériens et procédés associés
AU2013353581B2 (en) * 2012-12-06 2015-07-16 Colgate-Palmolive Company Oral gel for relief of tooth pain
CN108358991B (zh) * 2018-02-01 2020-11-10 云南中烟工业有限责任公司 一种澄广花中的三萜类化合物及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985601A (en) * 1995-06-05 1999-11-16 Human Genome Sciences, Inc. DNA encoding human cystatin E

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2750326B1 (fr) * 1996-06-28 1998-07-31 Oreal Composition cosmetique et/ou dermatologique acide contenant un poly(acide 2-acrylamido 2-methylpropane sulfonique) reticule et neutralise a au moins 90 %
US6264926B1 (en) * 1999-02-12 2001-07-24 Council Of Scientific And Industrial Research Formulation useful as a natural herbal tooth powder
US6669929B1 (en) * 2002-12-30 2003-12-30 Colgate Palmolive Company Dentifrice containing functional film flakes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985601A (en) * 1995-06-05 1999-11-16 Human Genome Sciences, Inc. DNA encoding human cystatin E

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110141572A (zh) * 2019-06-20 2019-08-20 牡丹江医学院 一种治疗哮喘的药物及其制备方法
CN110141572B (zh) * 2019-06-20 2020-05-12 牡丹江医学院 一种治疗哮喘的药物及其制备方法

Also Published As

Publication number Publication date
WO2006019881A3 (fr) 2006-09-08
WO2006010147A2 (fr) 2006-01-26
CA2573494A1 (fr) 2006-01-26
EP1773313A2 (fr) 2007-04-18
EP1773313A4 (fr) 2007-11-07
WO2006019881A2 (fr) 2006-02-23

Similar Documents

Publication Publication Date Title
GB0705434D0 (en) Control systems and methods for active controlled bottomhole pressure systems
EP1955240B8 (fr) Procédé de commande manuelle et autonome d'une pompe à perfusion
AU2003282681A1 (en) Manually-opened and latchable fluid control valve and methods of operation
WO2007037900A3 (fr) Cassette chirurgicale de mesure de la tension intraoculaire
WO2007037894A3 (fr) Contrôle de pression intraoculaire
WO2005117938A3 (fr) Methodes de traitement des pathologies oculaires
WO2007030743A3 (fr) Implants cochleaires contenant des cellules biologiques et utilisations de ces dernieres
WO2002056823A3 (fr) Therapie par oxydoreduction pour des tumeurs
AU2003259537A1 (en) Blood glucose level control
AU2003286146A1 (en) Method and devices for the control of the usage of content
AU2003239094A1 (en) Method for control of personal data
TW200806298A (en) Methods for modulating bladder function
WO2006010147A3 (fr) Gestion de la formation d'un biofilm
AU2002222737A1 (en) Annealing control primer system for regulating primer annealing specificity and its applications
AU2003239140A1 (en) Composition and method for controlling spore producing fungi and bacteria
AU2003220056A1 (en) Microbial control system
WO2007089612A3 (fr) Procédés et compositions pour le traitement et la prévention d'infections bactériennes
WO2007053731A3 (fr) Expression de protéines solubles du facteur viii chez les bactéries
EP2229946A3 (fr) Utilisation de la protéine stimulatrice de croissance KIAA1524
AU2003215827A1 (en) Method for controlling and regulating the operation of an actuator
AU2003232173A1 (en) Compounds and methods for controlling bacterial virulence
FI20030258L (fi) Glukosinolaattien entsymaattisen hajottamisen ohjaaminen maitohappobakteerien avulla
AU2004267928A1 (en) Yeast cell walls for the treatment or prevention of hyperglycemia or for the stabilisation of glycemia
AU2003297668A1 (en) Bacterial bioherbicide for control of grassy weeds
AU2003294624A1 (en) Directly controlled pressure control valve

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2573494

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005791709

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005791709

Country of ref document: EP